206 related articles for article (PubMed ID: 31323362)
1. Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts.
Ruiz-Irastorza G; Ruiz-Estevez B; Lazaro E; Ruiz-Arruza I; Duffau P; Martin-Cascon M; Richez C; Ugarte A; Blanco P
Autoimmun Rev; 2019 Sep; 18(9):102359. PubMed ID: 31323362
[TBL] [Abstract][Full Text] [Related]
2. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts.
Ruiz-Irastorza G; Ugarte A; Saint-Pastou Terrier C; Lazaro E; Iza A; Couzi L; Saenz R; Richez C; Porta S; Blanco P
Autoimmun Rev; 2017 Aug; 16(8):826-832. PubMed ID: 28564619
[TBL] [Abstract][Full Text] [Related]
3. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis.
Ruiz-Arruza I; Barbosa C; Ugarte A; Ruiz-Irastorza G
Autoimmun Rev; 2015 Oct; 14(10):875-9. PubMed ID: 26044819
[TBL] [Abstract][Full Text] [Related]
4. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus.
Ruiz-Irastorza G; García M; Espinosa G; Cabezas-Rodríguez I; Mitjavila F; González-León R; Sopeña B; Perales I; Pinilla B; Rodríguez-Carballeira M; López-Dupla JM; Callejas JL; Castro A; Tolosa C; Sánchez-García ME; Pérez-Conesa M; Navarrete-Navarrete N; Rodríguez AP; Herranz MT; Pallarés L;
Clin Exp Rheumatol; 2016; 34(3):466-72. PubMed ID: 26940538
[TBL] [Abstract][Full Text] [Related]
5. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study.
Ruiz-Arruza I; Lozano J; Cabezas-Rodriguez I; Medina JA; Ugarte A; Erdozain JG; Ruiz-Irastorza G
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):582-591. PubMed ID: 28704598
[TBL] [Abstract][Full Text] [Related]
6. Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort.
González-Echavarri C; Capdevila O; Espinosa G; Suárez S; Marín-Ballvé A; González-León R; Rodríguez-Carballeira M; Fonseca-Aizpuru E; Pinilla B; Pallarés L; Ruiz-Irastorza G;
Lupus; 2018 Dec; 27(14):2253-2261. PubMed ID: 30451641
[TBL] [Abstract][Full Text] [Related]
7. Prednisone in lupus nephritis: how much is enough?
Ruiz-Irastorza G; Danza A; Perales I; Villar I; Garcia M; Delgado S; Khamashta M
Autoimmun Rev; 2014 Feb; 13(2):206-14. PubMed ID: 24189280
[TBL] [Abstract][Full Text] [Related]
8. Seventy years after Hench's Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus.
Ruiz-Irastorza G; Ugarte A; Ruiz-Arruza I; Khamashta M
Lupus; 2020 Sep; 29(10):1155-1167. PubMed ID: 32539657
[TBL] [Abstract][Full Text] [Related]
9. Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone.
Gonzalez-Echavarri C; Pernas B; Ugarte A; Ruiz-Irastorza G
Lupus; 2014 Mar; 23(3):323-6. PubMed ID: 24531426
[TBL] [Abstract][Full Text] [Related]
10. Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort.
Ruiz-Irastorza G; Paredes-Ruiz D; Herrero-Galvan M; Moreno-Torres V; Hernandez-Negrin H; Ruiz-Arruza I; Leonard C; Richez C; Lazaro E
Arthritis Care Res (Hoboken); 2024 Mar; ():. PubMed ID: 38529678
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort.
Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Quintana R; Gómez-Puerta JA; Catoggio LJ; Alvarellos A; Saurit V; Borba E; Sato E; Costallat L; Da Silva NA; Iglesias-Gamarra A; Neira O; Reyes-Llerena G; Cardiel MH; Amigo MC; Acevedo-Vásquez E; Esteva-Spinetti MH; Alarcón GS; Pons-Estel BA
J Rheumatol; 2019 Oct; 46(10):1299-1308. PubMed ID: 30824636
[TBL] [Abstract][Full Text] [Related]
12. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
[TBL] [Abstract][Full Text] [Related]
13. Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor.
Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
Int J Rheum Dis; 2019 Mar; 22(3):468-472. PubMed ID: 30406967
[TBL] [Abstract][Full Text] [Related]
14. Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort.
Pimentel-Quiroz VR; Ugarte-Gil MF; Harvey GB; Wojdyla D; Pons-Estel GJ; Quintana R; Esposto A; García MA; Catoggio LJ; Cardiel MH; Barile LA; Amigo MC; Sato EI; Bonfa E; Borba E; Lavras Costallat LT; Neira OJ; Massardo L; Guibert-Toledano M; Chacón-Díaz R; Alarcón GS; Pons-Estel BA
Lupus; 2019 Aug; 28(9):1101-1110. PubMed ID: 31291843
[TBL] [Abstract][Full Text] [Related]
15. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus.
Galarza-Maldonado C; Kourilovitch MR; Molineros JE; Cardiel MH; Zurita L; Soroka NF; Yagur VY; Doukh N; Cervera R
Autoimmun Rev; 2010 Dec; 10(2):108-11. PubMed ID: 20804861
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus.
Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Inoue Y; Ueno M; Tanaka Y
Int J Rheum Dis; 2019 Mar; 22(3):434-442. PubMed ID: 30338639
[TBL] [Abstract][Full Text] [Related]
17. Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus.
Tselios K; Gladman DD; Touma Z; Su J; Anderson N; Urowitz MB
Arthritis Care Res (Hoboken); 2019 Jun; 71(6):822-828. PubMed ID: 30055090
[TBL] [Abstract][Full Text] [Related]
18. Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus.
Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
Intern Med; 2019 May; 58(9):1257-1262. PubMed ID: 30626831
[TBL] [Abstract][Full Text] [Related]
19. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
[TBL] [Abstract][Full Text] [Related]
20. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus.
Gao D; Hao Y; Mu L; Xie W; Fan Y; Ji L; Zhang Z
Rheumatology (Oxford); 2020 Nov; 59(11):3400-3407. PubMed ID: 32337549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
